Currently several clinical trials targeting BCL2 expression in prostate cancer are ongoing [44]; therefore CYP1A1 may be a promising target for prostate cancer treatment since it is closely associated with BCL2 expression. This evidence concerns the gene BCL2 and prostate cancer.